指南与共识胸部肿瘤

《中华医学会肿瘤学分会肺癌临床诊疗指南(2026版)》要点解读

[Interpretation of the Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)].
指南 / 共识 · Zhonghua Zhong Liu Za Zhi · 2026-01-01

该指南自2018年起由上海市胸科医院呼吸与危重症医学科牵头,联合全国50余家单位、100余位专家共同撰写并年度更新,新增推荐以中国国家药品监督管理局批准的适应证为主要依据,尤其重视中国患者临床研究数据。本文从筛查、病理、早期可手术、局部晚期不可手术及晚期患者治疗等方面对2026版指南进行要点解读。

要点

  • 指南年度更新,新增推荐主要依据中国国家药品监督管理局批准的适应证。
  • 指南尤其重视采纳基于中国患者所进行的临床研究数据。
  • 解读涵盖筛查、病理及早期可手术、局部晚期不可手术和晚期患者的治疗。

核心结论

  • 2026版指南在筛查、病理及各分期治疗方面进行年度更新,新增推荐以中国国家药品监督管理局批准的适应证为主要依据。

研究设计与样本

  • 由上海市胸科医院呼吸与危重症医学科牵头,联合全国50余家肺癌诊疗单位、100余位专家合作撰写并年度更新。

临床怎么用

  • 临床医生可参照该指南要点进行肺癌筛查、病理评估及早期可手术、局部晚期不可手术和晚期患者的治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To promote the standardization of clinical diagnosis and treatment of lung cancer in China and to apply the latest evidence-based medical evidence to clinical practice, since 2018, the Department of Respiratory and Critical Care Medicine of Shanghai Chest Hospital has taken the lead, in collaboration with more than 50 lung cancer treatment institutions and over 100 experts nationwide, to jointly draft the clinical practice guidelines for lung cancer, with annual updates. The newly added recommendations are primarily based on indications approved by the National Medical Products Administration of China. To enhance the practicality of the guideline, particular emphasis has been placed on adopting clinical research data derived from Chinese patients. Recently, the Clinical Practice Guidelines for Lung Cancer of the Oncology Society of Chinese Medical Association (2026 Edition) was published. To better present the key points of the guidelines to fellow professionals, this article provides a summary interpretation based on the latest version, covering screening, pathology and treatment for early-stage operable, locally advanced unresectable, and advanced-stage patients. 为促进中国肺癌临床诊疗的规范化,将最新的循证医学证据应用于临床诊疗,从2018年开始,由上海市胸科医院呼吸与危重症医学科牵头,联合全国50余家肺癌诊疗单位、100余位专家合作撰写肺癌临床诊疗指南,并进行年度更新。新增加的推荐以中国国家药品监督管理局批准的适应证为主要依据。为体现指南的实用性,本指南尤其重视采纳基于中国患者所进行的临床研究数据。近期,《中华医学会肿瘤学分会肺癌临床诊疗指南(2026版)》出版,为更好地向广大同行介绍指南要点,文章以最新指南为依据,从筛查、病理、早期可手术患者的治疗、局部晚期不可手术患者的治疗及晚期患者的治疗等方面,对指南进行要点解读。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang B, Zhong RB, Han BH, et al. [Interpretation of the Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42927946. doi:10.3760/cma.j.cn112152-20260705-00310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。